Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2021 | $11.00 → $10.00 | Buy | Roth Capital |
Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), t
LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today announced it plans to release its third quarter 2025 financial results after market close today, Wednesday, November 19, 2025. The Company will conduct a conference call at 5:00 pm Eastern time on November 19, 2025, to review the results and provide operational updates.
LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today released previously unpublished clinical data confirming that treatment with Vivos' FDA-cleared Daytime-Nighttime Appliance (DNA) can provide children with Attention-Deficit/Hyperactivity Disorder (ADHD) and OSA significant relief and improvement in their quality of life. Vivos' DNA appliance is the only FDA 510k cleared non-surgical, non-phar
3 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $10.00 from $11.00 previously
Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $11.00 from $12.00 previously
8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
10-Q - Vivos Therapeutics, Inc. (0001716166) (Filer)
LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Operations Integration, and Dr. Terry Jones as its new Senior Vice President of Human Resources. These hires demonstrate Vivos' commitment to the successful implementation and expansion of its new sleep testing center and direct patient treatment operations, highlighted by Vivos' recent acquisition of The Sleep Center of Nevada and Vivos' ongoing, active e
Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), t
LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today announced it plans to release its third quarter 2025 financial results after market close today, Wednesday, November 19, 2025. The Company will conduct a conference call at 5:00 pm Eastern time on November 19, 2025, to review the results and provide operational updates.
Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today reported
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)